Categories: News

CareDx Names Ankur Dhingra as New Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced the appointment of Ankur Dhingra as the company’s new Chief Financial Officer (CFO) effective March 25, 2021. As CFO, Ankur will lead CareDx’s global finance organization including treasury, tax, and other corporate functions, and report directly to President and Chief Executive Officer Reg Seeto.

Ankur brings over 25 years of finance and accounting experience to CareDx, including a track record of success in executing and influencing growth-oriented business strategies, deploying M&A policies, scaling businesses, and managing a global team of finance and accounting professionals. He joins the company from Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemical markets, where he was Vice President of Investor Relations since 2019 and, prior to that, Group CFO for Agilent’s Life Sciences and Applied Markets.

“I am delighted to welcome Ankur to CareDx. We are privileged to have such a talented professional as Ankur join us in the CFO role. We have built a strong finance team, and now we have completed the team with Ankur,” said Reg Seeto, President and Chief Executive Officer of CareDx. “His extensive financial and investor relations experience, along with a proven track record of execution, will assist in driving our business to the next level of operational growth and financial performance.”

“I’m very excited to join CareDx and contribute to the company’s mission of providing healthcare solutions along the entire transplant patient journey,” said Ankur. “It has been impressive to see CareDx scale its operations and grow during the pandemic. I look forward to working with Reg and the entire organization as the business continues to grow and scale in addressing the significant unmet medical needs of transplant patients.”

About CareDx

CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

CONTACTS:
CareDx, Inc.
Sasha King
Chief Marketing Officer
415-287-2393
sking@caredx.com

Investor Relations
Greg Chodaczek
347-610-7010
investor@caredx.com

Staff

Recent Posts

Restart Life Sciences Signs Binding LOI to Acquire The Holy Crap Foods Portfolio of Brands and Manufacturing Plant

Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Restart Life Sciences Corp. (CSE: HEAL)…

8 minutes ago

Functional Brands Inc. Launches Kirkman’s(R) Skin, Beauty & Anti-Aging Bundle: A Science-Backed Approach to Radiant, Resilient Skin

Comprehensive Formula Featuring Reduced Glutathione, Zinc Cream, Biotin, and Grapefruit Seed ExtractLake Oswego, Oregon--(Newsfile Corp.…

8 minutes ago

CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities

Houston, Texas--(Newsfile Corp. - December 22, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) (CBIH) announces…

1 hour ago

XRP Healthcare® Secures Global Trademark Protection at the Intersection of Healthcare Services and XRP-Powered Payments

Multi-jurisdiction trademark coverage reinforces XRP Healthcare's position across digital health, pharmacy networks, and XRP-based payment…

2 hours ago

Black Book Poll: “Governed AI” Emerges as the Deciding Factor in 2026 NHS Procurement

Respondents report approvals and evaluation readiness are now the bottlenecks driving demand for reusable safety…

2 hours ago

Hemogenyx Pharmaceuticals PLC Announces Update on Admission of Shares

LONDON, UK / ACCESS Newswire / December 22, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the…

2 hours ago